Fortis Life Sciences, AccuGenomics partner to expand Genomics portfolio

Fortis Life Sciences, a leading strategic platform firm offering expertise, capital, and operational resources to boost founder-driven life sciences organizations, has announced partnership with AccuGenomics in the United States, with co-exclusive rights in Europe.

Reportedly, the agreement will allow Fortis to assist in expanding customer access to AccuGenomics’ exclusive SNAQ-SEQ Internal Standards Technology, the sole commercial internal standards for next-gen sequencing.

As per sources, SNAQ-SEQ multiplex QC standards are vital for extremely sensitive NGS applications as they limit the necessity for more expensive external controls that occupy valuable space in assay design.

These standards are more precise because every sample has an internal control rather than depending on representative controls being used for the complete assay.

While commenting on the collaboration, Ken Yoon, Chief Operating Officer at Fortis, quoted that the team is thrilled to partner with a pioneering firm like AccuGenomics.

Ken commented that their patented technology will improvise the ability of users to rely on the sensitivity and accuracy of their results, particularly in the most demanding precision medical applications.

Ken added that expertise and technology of AccuGenomics and their operational and commercial abilities will form a highly strategic and complementary partnership.

Dan Dilks, Senior Vice President, Business Development at AccuGenomics stated that Fortis Life Sciences is well associated throughout therapeutic, diagnostics, and pharmaceutical discovery areas as a strategic delivery partner in the Europe and United States for AccuGenomics.

This would offer operational resources and expertise to help in the development and success of the firm.

Dan mentioned that their focus lies on improvising the sensitivity and accuracy of challenging liquid biopsy applications such as minimal residual disease (MRD) detection.

It has been mentioned that the partnership with Fortis will propel the adoption of differentiated internal spike in standard for targeted NGS assays such as MRD while offering clinicians and researchers improvised access to the SNAQ technology.

Source Credit:-